{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T03:11:19Z","timestamp":1762053079022,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Tetracycline class antibiotics are widely used for multiple skin diseases, including acne vulgaris, acne rosacea, cutaneous infections, inflammatory dermatoses, and autoimmune blistering disorders. Concerns about antibiotic resistance and protecting the human\/host microbiome beg the question whether broad-spectrum tetracyclines such as doxycycline and minocycline should be prescribed at such a high rate by dermatologists when a narrow-spectrum tetracycline derivative, sarecycline, exists. We evaluated the clinical effectiveness of oral sarecycline against cutaneous staphylococcal infections, eyelid stye, and mucous membrane pemphigoid to determine whether sarecycline is a viable option for clinicians to practice improved antibiotic stewardship. We observed significant improvement in staphylococcal infections and inflammatory dermatoses with courses of oral sarecycline as short as 9 days, with no reported adverse events. These clinical findings are consistent with in vitro microbiological data and anti-inflammatory properties of sarecycline. Our data provides a strong rationale for clinicians to use narrow-spectrum sarecycline rather than broad-spectrum tetracyclines as a first-line agent in treating staphylococcal skin infections and inflammatory skin diseases for which tetracyclines are currently commonly employed. Such advancement in the practice paradigm in dermatology will enhance antibiotic stewardship, reduce risk of antibiotic resistance, protect the human microbiome, and provide patients with precision medicine care.<\/jats:p>","DOI":"10.3390\/antibiotics11060722","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T07:05:07Z","timestamp":1653635107000},"page":"722","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0584","authenticated-orcid":false,"given":"Ayman","family":"Grada","sequence":"first","affiliation":[{"name":"Grada Dermatology Research, LLC, Chesterbrook, PA 19087, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Center of Medical Mycology, Integrated Microbiome Core, Department of Dermatology, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher","family":"Bunick","sequence":"additional","affiliation":[{"name":"Yale Department of Dermatology, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"ref_1","first-page":"18","article-title":"Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use","volume":"9","author":"Webster","year":"2016","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/der2.49","article-title":"Treating acne with the tetracycline class of antibiotics: A review","volume":"2","author":"Graber","year":"2021","journal-title":"Dermatol. Rev."},{"key":"ref_3","unstructured":"(2008). DORYX\u00ae (Doxycycline hyclate) Delayed-Release Tablets, 75 mg, 100 mg and 150 mg for Oral Use, Mayne Pharma International Pty. Ltd."},{"key":"ref_4","unstructured":"(2010). Minocin (Minocycline hydrochloride) for Oral Use, Triax Pharmaceuticals, LLC."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2010.10.004","article-title":"Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action","volume":"63","author":"Griffin","year":"2011","journal-title":"Pharmacol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0019-5154.190105","article-title":"Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology","volume":"61","author":"Pradhan","year":"2016","journal-title":"Indian J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajd.12075","article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","volume":"55","author":"Perret","year":"2014","journal-title":"Australas. J. Dermatol."},{"key":"ref_8","first-page":"1543","article-title":"Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances","volume":"6","author":"Francino","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1684\/ejd.2014.2309","article-title":"Antibiotic stewardship in dermatology: Limiting antibiotic use in acne","volume":"24","author":"Dreno","year":"2014","journal-title":"Eur. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Alkhawaja, E., Hammadi, S., Abdelmalek, M., Mahasneh, N., Alkhawaja, B., and Abdelmalek, S.M. (2020). Antibiotic resistant Cutibacterium acnes among acne patients in Jordan: A cross sectional study. BMC Dermatol., 20.","DOI":"10.1186\/s12895-020-00108-9"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"adv00295","DOI":"10.2340\/00015555-3654","article-title":"Antibiotic Susceptibility of Cutibacterium acnes Strains Isolated from Israeli Acne Patients","volume":"100","author":"Rimon","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/1346-8138.15940","article-title":"Increased prevalence of doxycycline low-susceptible Cutibacterium acnes isolated from acne patients in Japan caused by antimicrobial use and diversification of tetracycline resistance factors","volume":"48","author":"Aoki","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Collaborators","year":"2022","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrmicro3270","article-title":"Microbiological effects of sublethal levels of antibiotics","volume":"12","author":"Andersson","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41467-018-04059-1","article-title":"Evolution of high-level resistance during low-level antibiotic exposure","volume":"9","author":"Knopp","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s42003-020-01176-w","article-title":"Evolution of antibiotic resistance at low antibiotic concentrations including selection below the minimal selective concentration","volume":"3","author":"Stanton","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molcel.2010.01.003","article-title":"Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis","volume":"37","author":"Kohanski","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gullberg, E., Cao, S., Berg, O.G., Ilb\u00e4ck, C., Sandegren, L., Hughes, D., and Andersson, D.I. (2011). Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002158"},{"key":"ref_19","unstructured":"Healthcare Infection Control Practices Advisory Committee (2016). Antibiotic Stewardship Statement for Antibiotic Guidelines\u2013The Recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC)."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jaad.2016.06.057","article-title":"Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study","volume":"75","author":"Barbieri","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2018.4944","article-title":"Trends in Oral Antibiotic Prescription in Dermatology, 2008 to 2016","volume":"155","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2014.02.031","article-title":"A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: Investigating practice gaps and potential cost-savings","volume":"71","author":"Lee","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40265-019-1053-4","article-title":"Sarecycline: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1358\/dot.2019.55.10.3045040","article-title":"Sarecycline hydrochloride for the treatment of acne vulgaris","volume":"55","author":"Kaul","year":"2019","journal-title":"Drugs Today"},{"key":"ref_26","unstructured":"(2022, April 10). Drug Approval Package: Seysara (Sarecycline), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209521Orig1s000TOC.cfm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms","volume":"395","author":"Nguyen","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"20530","DOI":"10.1073\/pnas.2008671117","article-title":"Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome","volume":"117","author":"Batool","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bunick, C.G., Keri, J., Tanaka, S.K., Furey, N., Damiani, G., Johnson, J.L., and Grada, A. (2021). Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040439"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ghannoum, M.A., Long, L., Bunick, C.G., Del Rosso, J.Q., Gamal, A., Tyring, S.K., McCormick, T.S., and Grada, A. (2022). Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030324"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e01297-18","DOI":"10.1128\/AAC.01297-18","article-title":"Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris","volume":"63","author":"Zhanel","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rusu, A., and Buta, E.L. (2021). The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122085"},{"key":"ref_33","first-page":"987","article-title":"Once-Daily Oral Sarecycline 1.5 mg\/kg\/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials","volume":"17","author":"Moore","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_34","first-page":"E53","article-title":"Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study","volume":"12","author":"Pariser","year":"2019","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_35","first-page":"s6","article-title":"Oral Tetracyclines and Acne: A Systematic Review for Dermatologists","volume":"19","author":"Armstrong","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1099\/mic.0.040618-0","article-title":"Long-term impacts of antibiotic exposure on the human intestinal microbiota","volume":"156","author":"Jernberg","year":"2010","journal-title":"Microbiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.36849\/JDD.6628","article-title":"A Rare Case of Empedobacter Brevis Cutaneous Infection Treated Successfully with Oral Sarecycline","volume":"21","author":"Adjei","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e15275","DOI":"10.1111\/dth.15275","article-title":"Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy","volume":"35","author":"Grada","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jedlowski, P.M., and Jedlowski, M.F. (J. Am. Acad. Dermatol., 2022). Case\/noncase analysis of the FDA Adverse Events Reporting System suggests higher reporting odds of photosensitivity and esophageal symptoms for sarecycline than of those for other tetracyclines, J. Am. Acad. Dermatol., in press.","DOI":"10.1016\/j.jaad.2022.02.025"},{"key":"ref_40","unstructured":"(2020). SEYSARA\u00ae (Sarecycline) Tablets for Oral Use (Package Insert), Almirall LLC."},{"key":"ref_41","first-page":"424","article-title":"In vitro interferon-gamma release test in patients with drug-induced pemphigus","volume":"10","author":"Goldberg","year":"2008","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_42","first-page":"333","article-title":"Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study","volume":"17","author":"Leyden","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_43","first-page":"634","article-title":"Management of Truncal Acne with Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials","volume":"20","author":"Baldwin","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.36849\/JDD.5678","article-title":"Successful Treatment of Periorificial Dermatitis with Novel Narrow Spectrum Sarecycline","volume":"20","author":"Graber","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"426","DOI":"10.36849\/JDD.5923","article-title":"Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety","volume":"20","author":"Rosso","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-015-0516-5","article-title":"An Update on Medical Treatment Options for Hidradenitis Suppurativa","volume":"76","author":"Deckers","year":"2016","journal-title":"Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","article-title":"The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study","volume":"85","author":"Tzellos","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(17)30549-4","article-title":"Doxycycline: A first-line treatment for bullous pemphigoid?","volume":"389","author":"Grantham","year":"2017","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00403-021-02216-z","article-title":"Efficacy and safety of tetracyclines for pemphigoid: A systematic review and meta-analysis","volume":"314","author":"Jin","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_50","first-page":"549","article-title":"Doxycycline, a Well-Tolerated, Economic, and Effective Alternative for the First-Line Treatment of Bullous Pemphigoid","volume":"109","author":"Iranzo","year":"2018","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: A pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/jdv.17395","article-title":"European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology-Part II","volume":"35","author":"Schmidt","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/jocd.12903","article-title":"Global rosacea treatment guidelines and expert consensus points: The differences","volume":"18","author":"Juliandri","year":"2019","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/ICU.0000000000000706","article-title":"Ocular rosacea","volume":"31","author":"Redd","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaad.2006.03.023","article-title":"Childhood stye and adult rosacea","volume":"55","author":"Bamford","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0039-6257(96)80064-6","article-title":"Meibomian gland dysfunction","volume":"40","author":"Driver","year":"1996","journal-title":"Surv. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.12788\/cutis.0057","article-title":"Fighting acne for the fighting forces","volume":"106","author":"Brahe","year":"2020","journal-title":"Cutis"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/722\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:19:45Z","timestamp":1760138385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["antibiotics11060722"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11060722","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}